These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 31010298)

  • 1. Nonhemostatic Activities of Factor Xa: Are There Pleiotropic Effects of Anti-FXa Direct Oral Anticoagulants?
    Papadaki S; Tselepis AD
    Angiology; 2019 Nov; 70(10):896-907. PubMed ID: 31010298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban and apixaban induce clotting factor Xa fibrinolytic activity.
    Carter RLR; Talbot K; Hur WS; Meixner SC; Van Der Gugten JG; Holmes DT; Côté HCF; Kastrup CJ; Smith TW; Lee AYY; Pryzdial ELG
    J Thromb Haemost; 2018 Nov; 16(11):2276-2288. PubMed ID: 30176116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ischemic and Thrombotic Events Associated with Concomitant Xa-inhibiting Direct Oral Anticoagulants and Antiepileptic Drugs: Analysis of the FDA Adverse Event Reporting System (FAERS).
    Perlman A; Wanounou M; Goldstein R; Choshen Cohen L; Singer DE; Muszkat M
    CNS Drugs; 2019 Dec; 33(12):1223-1228. PubMed ID: 31686406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists.
    Desai NR; Cornutt D
    Hosp Pract (1995); 2019 Aug; 47(3):113-122. PubMed ID: 31317796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the Development of Novel Factor Xa Inhibitors: A Patent Review.
    Khadse AN; Sharma MK; Murumkar PR; Rajput SJ; Yadav MR
    Mini Rev Med Chem; 2018; 18(16):1332-1353. PubMed ID: 29692238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants.
    Spronk HM; de Jong AM; Crijns HJ; Schotten U; Van Gelder IC; Ten Cate H
    Cardiovasc Res; 2014 Mar; 101(3):344-51. PubMed ID: 24385341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies.
    Escolar G; Diaz-Ricart M; Arellano-Rodrigo E
    Drugs Today (Barc); 2017 May; 53(5):271-282. PubMed ID: 28650000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of anthranilamide-based derivatives as FXa inhibitors.
    Huang C; Wang W; Li Y; Zhang S; Meng F; Xu W; Yuan J; Chen L
    Oncotarget; 2017 Jun; 8(23):37186-37199. PubMed ID: 28415603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
    Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values.
    Siddiqui F; Tafur A; Ramacciotti LS; Jeske W; Hoppensteadt D; Ramacciotti E; Iqbal O; Fareed J
    Clin Appl Thromb Hemost; 2019; 25():1076029619863493. PubMed ID: 31298056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Concepts in anticoagulant therapy - past, present, and future].
    Graf L
    Ther Umsch; 2012 Nov; 69(11):611-5. PubMed ID: 23117663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the Efficacy and Safety of Direct Oral Anticoagulants in Japanese Patients-Analysis of Pharmaceuticals and Medical Devices Agency Data.
    Terayama Y
    J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1171-1181. PubMed ID: 28169097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?
    Lippi G; Favaloro EJ
    Clin Chem Lab Med; 2015 Feb; 53(2):185-97. PubMed ID: 25241734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation.
    Wang W; Yuan J; Fu X; Meng F; Zhang S; Xu W; Xu Y; Huang C
    Molecules; 2016 Apr; 21(4):491. PubMed ID: 27089317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimally modified human blood coagulation factor X to bypass direct factor Xa inhibitors.
    Schreuder M; Jourdi G; Veizaj D; Poole DA; Cheung KL; Poenou G; Verhoef D; Thomassen S; Janssen LFH; Stepanian A; Hackeng TM; Gaussem P; Reitsma PH; Geerke DP; Siguret V; Bos MHA
    J Thromb Haemost; 2024 Aug; 22(8):2211-2226. PubMed ID: 38729577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor Xa and thrombin induce endothelial progenitor cell activation. The effect of direct oral anticoagulants.
    Papadaki S; Sidiropoulou S; Moschonas IC; Tselepis AD
    Platelets; 2021 Aug; 32(6):807-814. PubMed ID: 32762584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting factor Xa and thrombin: impact on coagulation and beyond.
    Esmon CT
    Thromb Haemost; 2014 Apr; 111(4):625-33. PubMed ID: 24336942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding.
    Hu X; Xiao Y; Yu C; Zuo Y; Yang W; Wang X; Gu B; Li J
    Eur J Pharmacol; 2018 Apr; 825():85-91. PubMed ID: 29475063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement and reversal of the direct oral anticoagulants.
    Samuelson BT; Cuker A
    Blood Rev; 2017 Jan; 31(1):77-84. PubMed ID: 27625113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laboratory measurement of the direct oral anticoagulants.
    Dale BJ; Chan NC; Eikelboom JW
    Br J Haematol; 2016 Feb; 172(3):315-36. PubMed ID: 26492202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.